KYZATREX (oral testosterone undecanoate) now available in all states across the US


Screenshot (18110).png

Screenshot (18112).png

KYZATREX (testosterone undecanoate) is an oral testosterone replacement therapy specifically designed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, such as primary hypogonadism and hypogonadotropic hypogonadism 1112. Here is detailed information regarding its dosage, usage, side effects, price, and efficacy:

Dosage​

KYZATREX is available in capsule form in three dosage strengths: 100 mg, 150 mg, and 200 mg. The recommended starting dose is 200 mg taken orally twice daily, once in the morning and once in the evening, with food to enhance absorption 2412. Dosage adjustments are made based on serum testosterone levels measured 3 to 5 hours after the morning dose, at least 7 days after starting treatment or following a dose adjustment 45.

Usage​

KYZATREX capsules should be taken with food. The therapy is initiated only after confirming hypogonadism through appropriate tests that show serum testosterone concentrations below the normal range. It is important to monitor blood pressure regularly due to the risk of hypertension associated with its use 1012.

Side Effects​

Common side effects include increased blood pressure, which may necessitate the use of antihypertensive medications. Other potential side effects are acne, pain at the injection site, increased red blood cell count, and mood changes. Serious side effects may include major adverse cardiovascular events such as heart attacks and strokes11517.

Price​

The price of KYZATREX can vary depending on the pharmacy, insurance coverage, and dosage. It is advisable to consult with a healthcare provider or pharmacist for the most accurate pricing information.

Efficacy​

KYZATREX has shown high efficacy in clinical trials, with up to 96% of patients achieving normal testosterone levels within 90 days of treatment. The therapy effectively manages symptoms associated with testosterone deficiency, such as fatigue, low libido, and muscle loss 367. The formulation is designed to be absorbed through the lymphatic system, reducing the risk of liver toxicity commonly associated with oral testosterone treatments 18.

Additional Considerations​

KYZATREX carries a boxed warning regarding the potential for blood pressure increases and the associated risk of cardiovascular events. It is classified as a Schedule III controlled substance due to potential for misuse and abuse 1017. It is not indicated for use in women, particularly those who are pregnant, and it is not approved for treating low testosterone due to aging19.In summary, KYZATREX offers a significant advancement in the treatment of male hypogonadism, providing a convenient oral formulation that avoids the complications of other testosterone delivery methods like injections and gels. However, careful monitoring for side effects, particularly hypertension, is crucial.

Screenshot (18113).png

Screenshot (18114).png

Screenshot (18115).png
 
Does anyone have the study with oral T where the doctor talks about taking the second dose early afternoon?

There is no study using such dosing (early am/early afternoon) protocol.

Some uros especially Dr. Sun recommend such dosing protocol for some of their patients in order to maximize T levels during the day which would allow one to avoid the peak that would be achieved in the late evening after the second dose as some men may feel too amped up which can cause numerous issues for some especially when it comes to getting quality sleep.

I already posted the link for the interview with Dr. Sun in post #28 of this thread.


1717650983506.png
 
There is no study using such dosing (early am/early afternoon) protocol.

Some uros especially Dr. Sun recommend such dosing protocol for some of their patients in order to maximize T levels during the day which would allow one to avoid the peak that would be achieved in the late evening after the second dose as some men may feel too amped up which can cause numerous issues for some especially when it comes to getting quality sleep.

I already posted the link for the interview with Dr. Sun in post #28 of this thread.


View attachment 44844
Thanks I knew I saw it somewhere! Do you have any experience with this dosing schedule?
 
Amazon Pharmacy: CLARUS THERAPEUTICS JATENZO 237 MG CAPSULE (1 Capsule)

Amazon is showing a 30 day suppy is 600$. Thats seems sky high. I dont have any insurance, any other source? I called my doc and it will take 20 days for a new appointment after i missed my appointment call today....why is this 20x the price of normal testosterone?

I'm on Jatenzo @237 mg twice daily. I have libido and erections, not so on injections after a couple of weeks. The rapid and frequent spikes in hormones I believe is the reason for optimal response.

When on injections, I don't feel the anabolic effects even with similar hormone levels.

The other day I tested testosterone at 4 pm, 3 hours past my midpoint. I was still in the 400 range, having spent the morning and mid afternoon with testosterone at the top end of the ranges.

Jatenzo is the only formulation of TRT that has worked for me!
 
Amazon Pharmacy: CLARUS THERAPEUTICS JATENZO 237 MG CAPSULE (1 Capsule)

Amazon is showing a 30 day suppy is 600$. Thats seems sky high. I dont have any insurance, any other source? I called my doc and it will take 20 days for a new appointment after i missed my appointment call today....why is this 20x the price of normal testosterone?

Taking advantage here!

Forget amazon.

Things have recently changed here when it comes to the $$$ Jatenzo.

As I stated in a previous thread the cost for Jatenzo is absurd and luckily they were forced to offer a pay-out-of-pocket option recently due to trying to stay competitive with Kyzatrex and Tlando which already offered such.





1718406277970.png









 
Possible dose titration (Jatenzo or Kyzatrex) needs to be kept in mind when it comes to the cost as not everyone will fare well or hit a high enough T level with the starting doses.





Dose and impact of baseline characteristics.

The distribution of final doses is provided in Figure 3. The logistic regression analysis of the impact of baseline characteristics on final dose demonstrated that body weight and diabetic status were positively associated with higher final dose (⩽400, 600, or 800mg) with odds ratios of 3.928 (95% CI: 1.896–8.137) and 2.646 (95% CI: 1.111–6.300), respectively. In contrast, use of antihypertensive medication had no influence on final dose.


Figure 3. Final dose distributions after 90 days of treatment with KYZATREX
Screenshot (36805).png






*Overall, 316 mg TU BID quickly and effectively increased serum T concentrations above 450 ng/dL in 77% of hypogonadal men. The wide distribution of serum T concentrations for the same dose (e.g., 23% <450 ng/dL and 27% 1000 ng/dL) suggests that men likely respond differently to T replacement therapy. Future studies and investigations should evaluate patient factors that impact the magnitude of T increases allowing for more individualized titrations.





Screenshot (36798).png

Screenshot (36799).png

1718418032432.png






Screenshot (36800).png

Screenshot (36801).png

Screenshot (36802).png
 
Possible dose titration (Jatenzo or Kyzatrex) needs to be kept in mind when it comes to the cost as not everyone will fare well or hit a high enough T level with the starting doses.





Dose and impact of baseline characteristics.

The distribution of final doses is provided in Figure 3. The logistic regression analysis of the impact of baseline characteristics on final dose demonstrated that body weight and diabetic status were positively associated with higher final dose (⩽400, 600, or 800mg) with odds ratios of 3.928 (95% CI: 1.896–8.137) and 2.646 (95% CI: 1.111–6.300), respectively. In contrast, use of antihypertensive medication had no influence on final dose.


Figure 3. Final dose distributions after 90 days of treatment with KYZATREX
View attachment 45318






*Overall, 316 mg TU BID quickly and effectively increased serum T concentrations above 450 ng/dL in 77% of hypogonadal men. The wide distribution of serum T concentrations for the same dose (e.g., 23% <450 ng/dL and 27% 1000 ng/dL) suggests that men likely respond differently to T replacement therapy. Future studies and investigations should evaluate patient factors that impact the magnitude of T increases allowing for more individualized titrations.





View attachment 45307
View attachment 45308
View attachment 45309





View attachment 45310
View attachment 45311
View attachment 45312





Conclusions:

Overall, the starting dose of 237 mg TU BID quickly and effectively increased serum T concentrations ≥300 ng/dL in 85% of hypogonadal men. The wide distribution of serum T concentrations for the same dose (e.g., 15% <300 ng/d and 12% ≥1000 ng/dL) suggests that men likely respond differently to T replacement therapy. Therefore, an oral T replacement therapy that allows for dose titration would likely be preferable to a fixed dose. Future studies and investigations should evaluate patient factors that impact the magnitude of T increases allowing for more individualized titrations.




Screenshot (40401).webp
 

00:29:13 - Oral vs Injectable Testosterone: Benefits and Comparisons

01:05:55 - Kyzatrex: A New Approach to Testosterone Delivery





If your goal is to minimize chances of driving up hematocrit let alone hitting a high-end short-lived daily peak twice daily then 400 mg BID is most likely the way to achieve such unless you are one of those hyper responders who will fare well on a lower daily dose!



*At a mean follow up time of 6 months, patients demonstrated a significant increase in TT (263 to 798 ng/dL), drop in SHBG (32.4 to 17.83 nmol/L), and increase in calculated fT (7.24 to 26.74 ng/dL). FSH and LH, while lower, were maintained at non-zero levels (FSH from 5.7 to 2.9 mIU/mL and LH from 3.3 to 1.9 mIU/mL). Estradiol modestly increased (20.5 to 24.7 pg/mL) while hematocrit did not significantly increase (44.9% to 47.4%). No patients reported testicular atrophy or were initiated on aromatase inhibitors. One patient had a hematocrit rise above 52% (53.2%) and was reduced to 300 mg BID.

* Initiating oral TU therapy with Kyzatrex at 400 mg BID is safe and effective in achieving therapeutic serum testosterone levels. The high dose was well-tolerated and resulted in substantial symptom improvement, high patient satisfaction, and adherence. These findings support considering a higher starting dose for hypogonadal men considering oral TU therapy.





 

Online statistics

Members online
9
Guests online
79
Total visitors
88

Latest posts

Back
Top